CN108272781B - Application of cardamonin in preparing medicine for preventing and treating alopecia - Google Patents
Application of cardamonin in preparing medicine for preventing and treating alopecia Download PDFInfo
- Publication number
- CN108272781B CN108272781B CN201810064538.7A CN201810064538A CN108272781B CN 108272781 B CN108272781 B CN 108272781B CN 201810064538 A CN201810064538 A CN 201810064538A CN 108272781 B CN108272781 B CN 108272781B
- Authority
- CN
- China
- Prior art keywords
- hair
- cardamonin
- group
- skin
- minoxidil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- NYSZJNUIVUBQMM-BQYQJAHWSA-N Cardamonin Chemical compound COC1=CC(O)=CC(O)=C1C(=O)\C=C\C1=CC=CC=C1 NYSZJNUIVUBQMM-BQYQJAHWSA-N 0.000 title claims abstract description 49
- NYSZJNUIVUBQMM-UHFFFAOYSA-N alpinetin chalcone Natural products COC1=CC(O)=CC(O)=C1C(=O)C=CC1=CC=CC=C1 NYSZJNUIVUBQMM-UHFFFAOYSA-N 0.000 title claims abstract description 35
- 201000004384 Alopecia Diseases 0.000 title claims abstract description 32
- 239000003814 drug Substances 0.000 title claims abstract description 19
- 231100000360 alopecia Toxicity 0.000 title claims abstract description 16
- 201000002996 androgenic alopecia Diseases 0.000 claims description 8
- 208000024963 hair loss Diseases 0.000 claims description 8
- 230000003676 hair loss Effects 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 210000004209 hair Anatomy 0.000 description 84
- 210000003491 skin Anatomy 0.000 description 44
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 35
- 230000000694 effects Effects 0.000 description 33
- 241000699670 Mus sp. Species 0.000 description 27
- 230000003779 hair growth Effects 0.000 description 19
- 210000003780 hair follicle Anatomy 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 15
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 14
- 229960003632 minoxidil Drugs 0.000 description 14
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 14
- 229940116852 myricetin Drugs 0.000 description 14
- 235000007743 myricetin Nutrition 0.000 description 14
- PLZVEHJLHYMBBY-UHFFFAOYSA-N Tetradecylamine Chemical compound CCCCCCCCCCCCCCN PLZVEHJLHYMBBY-UHFFFAOYSA-N 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 9
- 240000002943 Elettaria cardamomum Species 0.000 description 8
- 235000005300 cardamomo Nutrition 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 230000001575 pathological effect Effects 0.000 description 8
- 206010068168 androgenetic alopecia Diseases 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 229960003604 testosterone Drugs 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000011740 C57BL/6 mouse Methods 0.000 description 5
- 230000003698 anagen phase Effects 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 230000002951 depilatory effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- -1 flavonoid compound Chemical class 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 238000001543 one-way ANOVA Methods 0.000 description 4
- 230000001256 tonic effect Effects 0.000 description 4
- 241000490499 Cardamine Species 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 238000012935 Averaging Methods 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- WUADCCWRTIWANL-UHFFFAOYSA-N biochanin A Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O WUADCCWRTIWANL-UHFFFAOYSA-N 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000003778 catagen phase Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000035617 depilation Effects 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000000118 hair dye Substances 0.000 description 2
- 239000008266 hair spray Substances 0.000 description 2
- 238000010150 least significant difference test Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- OKJCFMUGMSVJBG-ABEVXSGRSA-N Delta(1)-dihydrotestosterone Chemical compound C1C(=O)C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 OKJCFMUGMSVJBG-ABEVXSGRSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940056582 human hair preparation Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000003170 nutritional factors Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to the field of medicine, in particular to a medical application of cardamonin. The cardamonin can be used for preventing and treating alopecia.
Description
Technical Field
The invention belongs to the field of medicine. In particular to the application of the bean-shaped cardamine in the preparation of the medicine for preventing and treating the alopecia.
Background
Alopecia is the phenomenon of hair loss, and is divided into physiological and pathological. Physiological alopecia refers to the phenomenon of normal hair loss, which is usually the hair in the catagen and telogen phases, and the normal amount of hair can be maintained because the hair in the catagen and growth phases is constantly in dynamic balance. The pathologic alopecia refers to abnormal or excessive hair loss, and the factors causing pathologic alopecia include heredity, mental stress, acute and chronic infectious diseases, various dermatoses, endocrine disturbance, physicochemical factors, nerve factors, and nutritional factors.
Androgenetic alopecia is mostly seen in young and strong male with the age of 20-30 years, is characterized by progressive reduction of hair on the head and the top, mostly appears in adolescence, is aggravated along with age symptoms, affects 60-70% of the population worldwide, and the incidence rate in European and American countries is obviously higher than that in China. Alopecia can have a significant impact on an individual's mental well-being and quality of life. Androgenetic alopecia is a source of low self-esteem and anxiety in many patients, with severe cases leading to depression.
Cardamonin, also called cardamonin or cardamochalcone, is a flavonoid compound isolated from katsumadai seed, and has antiinflammatory, antibacterial, antioxidant and anticancer activities.
Disclosure of Invention
The purpose of the invention is to provide a novel medical use of a bean-frame-shaped incense.
In particular, the present invention provides the use of a Francis Fragrans Francis in the manufacture of a medicament for the prevention and treatment of hair loss.
In a preferred embodiment, the mixture of the bean-flavor and the main ingredient is used as the sole active ingredient in the preparation of a medicament for preventing or treating alopecia.
In another preferred embodiment, the alopecia is androgenetic alopecia.
The details of various aspects of the invention are set forth in subsequent sections. The features, objects, and advantages of the invention will be apparent from the description and from the claims.
Drawings
FIG. 1 shows the effect of myristyl amine on mouse body weight.
Figure 2 shows the effect of myridamine on hair length.
Figure 3 demonstrates the effect of myricetin on skin color.
FIG. 4 shows the effect of myristyl amine on the gross weight of mice.
FIG. 5 shows the effect of myricetin on skin tissue of mice.
FIG. 6 shows the effect of myristyl amine on mouse body weight.
Figure 7 demonstrates the effect of myricetin on hair length.
Figure 8 demonstrates the effect of myricetin on skin color and hair growth.
FIG. 9 shows the effect of myristyl amine on the gross weight of mice.
FIG. 10 shows the effect of myricetin on skin tissue of mice.
Detailed Description
The invention arose in part from the unexpected discovery that: the fructus Amomi rotundus can be used for preparing medicine for preventing and treating alopecia.
Further, the present invention provides the use of a Francis Doumbellate in the manufacture of a medicament for the prevention or treatment of hair loss.
The molecular formula of cardamonin is as follows: C16H14O4, molecular weight: 270.28, having the formula:
the cardamine of the present invention is commercially available from Sigma chemical Co., Dowman Biotech Co., Ltd. The purity of the product meets the pharmaceutical standard. The purity of myricetin is best > 98%.
The cardamonin of the present invention may be used alone or in the form of a pharmaceutical composition. The pharmaceutical composition comprises the cardamonin of the present invention as an active ingredient and a pharmaceutically acceptable carrier. Preferably, the pharmaceutical composition of the present invention contains 0.1 to 99.9% by weight of the cardamonin of the present invention as an active ingredient. The pharmaceutical carrier does not destroy the pharmaceutical activity of the cardamonin, and the effective dosage of the cardamonin is nontoxic to human body when the pharmaceutical carrier acts.
Such pharmaceutically acceptable carriers include, but are not limited to: lecithin, aluminum stearate, alumina, ion exchange materials, self-emulsifying drug delivery systems, tweens or other surfactants, serum proteins, buffer substances such as phosphates, glycine, sorbic acid, water, salts, electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, magnesium silicate, mixtures of saturated fatty acid partial glycerides, and the like.
Other conventional pharmaceutical adjuvants such as binder (e.g. microcrystalline cellulose), filler (e.g. starch, glucose, anhydrous lactose and lactose beads), disintegrant (e.g. crosslinked PVP, croscarmellose sodium, low-substituted hydroxypropylcellulose), lubricant (e.g. magnesium stearate), and absorption enhancer, adsorption carrier, flavoring agent, sweetening agent, excipient, diluent, wetting agent, etc.
The cardamonin and pharmaceutical compositions thereof of the present invention may be prepared according to conventional methods in the art and may be administered by the gastrointestinal or parenteral or topical dermal route. The oral preparation comprises capsule, tablet, oral liquid, granule, pill, powder, pellet, and unguent; parenteral preparations include injections and the like; topical skin preparations include ointments, plasters, rubber plasters, pastes, liniments, lotions, plastics, iontophoresis agents, and the like. Topical dermal formulations are preferred.
The administration route of the cardamonin and the pharmaceutical composition thereof can be oral, sublingual, transdermal, intramuscular or subcutaneous, skin mucosa and the like.
Besides preparing into medicament, the cardamonin can be added with various food additives such as antioxidant, pigment, enzyme preparation and the like to prepare health food or health cosmetics according to the conventional method in the field.
The cosmetic composition may be in a form selected from the group consisting of hair tonic, hair conditioner, hair essence, hair lotion, hair tonic lotion, shampoo, hair dye, hair cream, hair tonic, hair nourishing cream, hair moisturizing cream, hair massage cream, hair wax, hair gas, hair spray, hair mask, hair tonic, hair soap, hair cleansing foam, hair oil, hair drying agent, hair conditioner, hair dye, hair curling preparation, hair bleach, hair gel, hair glaze, hair dressing, hair sticking agent, hair moisturizer, hair mousse, and hair spray.
The invention will be further illustrated with reference to the following specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. The experimental procedures, in which specific conditions are not noted in the following examples, are generally carried out according to conventional conditions or according to conditions recommended by the manufacturers. All percentages, ratios, proportions, or parts are by weight unless otherwise specified.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In addition, any methods and materials similar or equivalent to those described herein can be used in the methods of the present invention. The preferred embodiments and materials described herein are intended to be exemplary only.
The features mentioned above with reference to the invention, or the features mentioned with reference to the embodiments, can be combined arbitrarily. All the features disclosed in this specification may be combined in any combination and each feature disclosed in this specification may be replaced by alternative features serving the same, equivalent or similar purpose. Thus, unless expressly stated otherwise, the features disclosed are merely generic examples of equivalent or similar features.
Example one
1. Experimental Material
1.1 medicinal materials
Cardamonin (CAS: 18956-16-6, molecular weight 270.28, HPLC purity ≥ 98%, WUDEMASTET Biotech, Inc.); minoxidil (CAS: 38304-91-5, HPLC purity is not less than 98%, Shanghai-sourced leaf Biotech limited); vetting depilatory cream (guo yu tejia G20161330, lijie time home (china) ltd);
1.2 Experimental animals
C57BL/6 male mice weighing 20 ± 2g (8 weeks), provided by the experimental animals center of the university of medicine in shanghai, animal certification No.: SYXK (Shanghai) 2009-0069. Placing in conventional breeding environment, and freely taking food and drinking water.
2. Experimental methods
2.1 general alopecia mouse model establishment
A reference for establishing a hair loss mouse model (influence of crinis Carbonisatus on hair growth of C57BL/6 mice; Chinese medicine J2017 (07): 3273-5.). A C57BL/6 male mouse (20 + -2 g) with uniform body weight was selected and acclimated for 1 week, and the hair on the back of the mouse was removed with a depilatory cream to an area of about 4 cm. times.3 cm to induce the hair follicle of the mouse to move from the resting stage to the anagen stage, where the hair follicle was morphologically indistinguishable from the spontaneously formed anagen hair follicle and the skin was pink. The experimental area on the back of each group of mice was plated the following way the following day of hair removal. The sample coating method comprises the following steps:
model group: coating blank substrate
Minoxidil group: 2% Minoxidil
Cardamonin group: coating 2% cardamonin
During the test period, the dosage formulations were freshly prepared daily with 75% ethanol and used within 1 hour of preparation.
2.2 evaluation index
2.2.1 Hair Length measurement: the application of the medicines 1d, 5d, 7d, 10d, 12d, 14d and 16d, respectively, was performed by removing 3 hair strands from the front, middle and rear portions of the depilated area, measuring the lengths thereof, and averaging the lengths.
2.2.2 skin color and Hair growth status: applying the medicines 1d, 5d, 7d, 10d, 12d, 14d and 16d, photographing, and observing the color of the skin and the growth condition of the hair.
2.2.3 gross weight measurement: after day 16 the mice were sacrificed and 2 x 2cm area of hair was cut along the hair roots in the epilated area and weighed on an analytical balance.
2.2.4 histopathological section: on day 16, 1cm × 1cm of skin tissue was taken from the mouse depilated area, fixed in 4% formalin, prepared as a conventional HE pathological section and photographed.
2.3 statistical analysis
All experimental data were repeated 3 times, the results were expressed as mean ± standard deviation, and One-way analysis of variance (One-way ANOVA) and LSD test were performed on the experimental data using SPSS 16.0 statistical software, with P <0.05 being statistically significantly different.
3. Results
3.1 Effect of Amomum cardamomum on body weight
FIG. 1 shows the effect of myristyl amine on mouse body weight. The weight of the minoxidil mice obviously increases along with the time, which shows that the minoxidil can increase the weight of the mice as hormone. Compared to the model group, cardamonin had no significant effect on mouse body weight.
3.2 Effect of Amomum cardamomum on Hair growth
Figure 2 shows the effect of myridamine on hair length. The hair lengths of the model at 12, 14 and 16 days were selected for analysis, and it was found that the hair growth promotion of minoxidil and myricetin was significantly different at 14 days (P <0.01) compared with the model group. The difference between the two groups and the model group was more pronounced at day 16 (cardamonin group P <0.01, minoxidil group P < 0.001). The above shows that cardamonin can stimulate hair growth.
3.3 effects of myricetin on Hair growth status and skin color.
Fig. 3 shows the effect of cardamonin on hair growth and skin color. At day 7, the skin of the minoxidil and myristyl mice began to develop black spots, indicating that the skin of the mice began to grow hair; day 10 minoxidil group had a large number of black spots appearing, the skin started to turn black from pink, while myriamel group also appeared black spots and was more numerous than the model group; the differences between the three groups were more evident at day 12, with the minoxidil and cardamom hair removal zones being substantially full of black, hair and hair growth, and the skin portions of the model hair removal zones still being pink. On day 14, the minoxidil group and the myristyl group had most of the hair growing out of the skin, the skin had become dark, and the model group had hair growing out but had most of the skin with dark hair and short hair; on day 16, the skin of the backs of the minoxidil group and the myriamectin group is basically full of hair and long, and the skin of a part of mice in the model group is only blackened and the hair is short. The results show that the cardamonin can accelerate the skin blackening of the back of the mouse and stimulate the rapid growth of hair.
3.4 Effect of Amomum cardamomum on Hair weight
FIG. 4 shows the effect of myristyl amine on the gross weight of mice. On day 16, mice were sacrificed, depilated areas were selected, 2 x 2cm area of hair was cut, and the weight of cardamonin group hair was 61.10 + -15.55 mg, minoxidil group hair was 52.19 + -20.55 mg, and model group hair was 10.65 + -3.34 mg when weighed on an analytical balance. Compared with the model group, the cardamonin group and the minoxidil group have significant differences (P <0.01 in the cardamonin group and P <0.001 in the minoxidil group), and both can obviously increase the weight of hair. Indicating that myristyl amine can stimulate hair growth.
3.5 Effect of Amomum cardamomum on skin histopathology
FIG. 5 shows the effect of myricetin on skin tissue of mice. Pathological sections are made 16 days after depilation, and from the observation of transverse cutting and longitudinal cutting, the hair follicles of the model group are fewer, the lower ends of the hair follicles are degenerated, and the hair follicles are sparser. The cardamonin and minoxidil groups had a large number of hair follicles, which were long and large, and had dense hair follicles. Therefore, the cardamonin can improve the phenomenon of hair follicle quantity reduction caused by molding, and further stimulate the growth of hair.
The results of the study show that the cardamonin can stimulate the growth of hair and treat general alopecia.
Example two
1. Experimental Material
1.1 medicinal materials
Cardamonin (CAS: 18956-16-6, molecular weight 270.28, HPLC purity ≥ 98%, WUDEMASTET Biotech, Inc.); minoxidil (CAS: 38304-91-5, HPLC purity is not less than 98%, Shanghai-sourced leaf Biotech limited); testosterone (CAS: 58-22-0, molecular weight 288.42, HPLC purity 98% or more, manufactured by Sigma-Aldrich, USA);
1.2 Experimental animals
C57BL/6 male mice weighing 20 ± 2g (8 weeks), provided by the experimental animals center of the university of medicine in shanghai, animal certification No.: SYXK (Shanghai) 2009-0069. Placing in conventional breeding environment, and freely taking food and drinking water.
2. Experimental methods
2.1 Testosterone-induced androgenetic alopecia mouse model establishment
Reference is made to the establishment of testosterone-induced androgenetic alopecia mouse models (preliminary study of the effects of biochanin A on the hair growth of mice as models of pathological alopecia. Natural products research and development (04): 613-618). A C57BL/6 male mouse (20 + -2 g) with uniform body weight was selected and acclimated for 1 week, and hair was removed with a depilatory cream to induce the mouse hair follicle to enter the anagen phase from the resting phase, wherein the hair follicle was morphologically indistinguishable from the spontaneously developing anagen phase and the skin was pink. The experimental area on the back of each group of mice was plated the following way the following day of hair removal. The sample coating method comprises the following steps:
model group: coating 0.1% testosterone for 30min, and coating blank matrix;
cardamonin group: coating 0.1% testosterone for 30min, and coating 2% myricetin;
minoxidil group: applying 0.1% testosterone for 30min, and applying 2% minoxidil;
during the test period, the dosage formulations were freshly prepared daily with 75% ethanol and used within 1 hour of preparation.
2.2 evaluation index
2.2.1 Hair Length measurement: the application of the medicines 1d, 6d, 9d, 12d, 15d, 18d and 21d, respectively, was performed by removing 3 hair strands from the front, middle and rear portions of the depilated area, measuring the lengths thereof, and averaging the lengths.
2.2.2 skin color and Hair growth status: applying the medicines 1d, 6d, 9d, 12d, 15d, 18d and 21d, photographing, and observing the color of the skin and the growth condition of the hair.
2.2.3 gross weight measurement: after day 21, the mice were sacrificed and 2 x 2cm area of hair was cut along the hair roots in the depilated area and weighed on an analytical balance.
2.2.4 histopathological section: on day 21, 1cm × 1cm of skin tissue was taken from the mouse depilated area, fixed in 4% formalin, prepared as a conventional HE pathological section and photographed.
2.3 statistical analysis
All experimental data were repeated 3 times, the results were expressed as mean ± standard deviation, and One-way analysis of variance (One-way ANOVA) and LSD test were performed on the experimental data using SPSS 16.0 statistical software, with P <0.05 being statistically significantly different.
3. Results
Therapeutic effect of cardamonin on testosterone induced androgenetic alopecia mice
3.1 Effect of Amomum cardamomum on body weight
FIG. 6 shows the effect of myristyl amine on mouse body weight. The weight of the minoxidil mice is obviously increased, and the significant difference is more than that of the model group (P <0.05, P <0.01 and P < 0.001); compared to the model group, cardamonin had no significant effect on mouse body weight.
3.2 Effect of Amomum cardamomum on Hair growth
Figure 7 demonstrates the effect of myricetin on hair length. The hair lengths of the model days 15, 18 and 21 are selected for analysis, and the result shows that the minoxidil promotes the hair growth by the day 15 and has a remarkable difference (P <0.01) compared with the model group, while the myricetin does not have a difference with the model group. The cardamonin group, the minoxidil group and the model group are obviously different at day 18 (P < 0.01); the difference between the two groups and the model group was more pronounced at day 21 (myridamine group P <0.01, minoxidil group P < 0.001). The above shows that cardamonin can stimulate hair growth.
3.3 effects of myricetin on Hair growth status and skin color.
FIG. 8 shows the effect of cardamonin on hair growth and skin color. At day 6, the skin of the minoxidil group mice began to have black spots, indicating that the skin of the mice began to have hair growing, while the other two groups did not appear; day 9 minoxidil group had a large number of black spots appearing, the skin started to turn black from pink, while myriamel group also appeared black spots and was more numerous than the model group; the differences between the three groups were more obvious at day 12, the depilatory area of the minoxidil group was substantially full of black, the cardamine also had a majority of the skin changed from pink to black, and the model group had a majority of the skin also pink. On day 15, the minoxidil group and the myristyl group had most of the hair growing out of the skin, the skin had turned black, and the model group had hair growing out but most of the skin was pink; the skin of the back of the minoxidil group on the 18 th day and the 21 st day is basically full of hair and is longer, and the skin of the back of the myriamectin group is also more hair but is shorter than the minoxidil; some of the mice in the model group had only black skin and shorter hair. The results show that the cardamonin can accelerate the skin blackening of the back of the mouse and stimulate the rapid growth of hair.
3.4 Effect of Amomum cardamomum on Hair weight
FIG. 9 shows the effect of myristyl amine on the gross weight of mice. On day 21, mice were sacrificed, depilated areas were selected, 2 x 2cm area of hair was cut, and analytical balance weighing found that the cardamonin group had a hair weight of 46.06 ± 13.12mg, the minoxidil group had a hair weight of 62.02 ± 6.39mg, and the model group had a hair weight of 11.54 ± 7.21 mg. Compared with the model group, the cardamonin group and the minoxidil group have significant differences (P <0.01 in the cardamonin group and P <0.001 in the minoxidil group) compared with the model group, and both can obviously increase the weight of the hair. Indicating that myristyl amine can stimulate hair growth.
3.5 Muramanning skin histology
FIG. 10 shows the effect of myricetin on skin tissue of mice. Pathological sections are made 21 days after depilation, and from the observation of transverse cutting and longitudinal cutting, the hair follicles of the model group are fewer, the lower ends of the hair follicles are degenerated, and the hair follicles are sparser. The cardamonin and minoxidil groups had a large number of hair follicles, which were long and large, and had dense hair follicles. Thus, cardamonin can improve the phenomenon of decrease in the number of hair follicles caused by androgen, and further stimulate the growth of hair.
The results of the study show that cardamonin can stimulate hair growth and treat androgenetic alopecia caused by testosterone.
The various aspects of the invention are addressed above. It should be understood, however, that equivalent changes and modifications may be made thereto by those skilled in the art without departing from the spirit of the present invention, and that such changes and modifications are intended to be covered by the appended claims.
Claims (2)
1. Use of a cardamomin in the manufacture of a medicament for the prevention and treatment of hair loss, said cardamomin being the sole active ingredient in the manufacture of a medicament for the prevention and treatment of hair loss.
2. The use of claim 1, wherein the alopecia is androgenic alopecia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2017111757837 | 2017-11-22 | ||
| CN201711175783 | 2017-11-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108272781A CN108272781A (en) | 2018-07-13 |
| CN108272781B true CN108272781B (en) | 2020-08-28 |
Family
ID=62804705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810064538.7A Expired - Fee Related CN108272781B (en) | 2017-11-22 | 2018-01-23 | Application of cardamonin in preparing medicine for preventing and treating alopecia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108272781B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112400797B (en) * | 2020-11-19 | 2022-03-22 | 北京科技大学 | Rapid construction method of androgen alopecia animal model |
| CN112915176B (en) * | 2021-03-22 | 2022-01-14 | 上海中医药大学 | Alpinia katsumadai composition for preventing and treating alopecia |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1219884B (en) * | 1988-03-28 | 1990-05-24 | Helga Frey | COMPOSITION OF HAIR LOTION PROCEDURE FOR ITS PRODUCTION AND USE |
| KR102212633B1 (en) * | 2013-11-29 | 2021-02-08 | (주)아모레퍼시픽 | Cosmetic composition containing essential oil for preventing stress alopecia |
| WO2017131955A1 (en) * | 2016-01-27 | 2017-08-03 | Elc Management Llc | Personal care composition comprising a hair restorative blend |
| CN108883042B (en) * | 2016-01-27 | 2021-10-29 | Elc 管理有限责任公司 | Method of treating the appearance of open hair |
-
2018
- 2018-01-23 CN CN201810064538.7A patent/CN108272781B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN108272781A (en) | 2018-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108272781B (en) | Application of cardamonin in preparing medicine for preventing and treating alopecia | |
| EP3103435A1 (en) | Composition for promoting hair growth or preventing hair loss | |
| KR20160029769A (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing Hydroxydecanoic acid | |
| JP2004091354A (en) | Hair tonic | |
| CN109044996B (en) | Medical application of schisandrin | |
| JPH0363225A (en) | Use of 5'-dioxy-5'-methylthioadeno- sine, s-adenosylmethionine and their salts in preparation of drog compouhd which stimulates hair growth of patient suffering from baldhess as wellas related drug compounds | |
| KR20150085968A (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing Sinomenine Hydrochloride | |
| EP3991734A1 (en) | Agent for promoting hair growth | |
| CN112915176B (en) | Alpinia katsumadai composition for preventing and treating alopecia | |
| AU2019339488A1 (en) | Uses of plasminogen activator inhibitor 1 (PAI-1) inhibitors | |
| KR101578849B1 (en) | Shampoo or conditioner composition containing Ginsenoside C-Mx1 for promoting hair growth by strengthen the scalp and the hair roots | |
| KR102386651B1 (en) | Composition for preventing or treating hair loss comprising tiplaxtinin | |
| KR100476069B1 (en) | A composition for trichogenousness or preventing the depilation containing 1,2-dithiolthione derivative | |
| KR100308491B1 (en) | Composition for growthing hair | |
| KR101651248B1 (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing Forsythin | |
| CN113041246A (en) | Curcumin composition for preventing and treating alopecia | |
| KR102000935B1 (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing 5-hydroxytryptophan | |
| WO2021105695A1 (en) | New use of angiotensin ii receptor agonist | |
| CN113546129A (en) | New use of Bulbus Allii Macrostemi extract | |
| CN117860713A (en) | Application of alpha-pinene and oxidation product thereof in preparing hair loss prevention and hair growth medicament | |
| KR20150085964A (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing Wogonin | |
| JPH1077216A (en) | Hair-restoring cosmetic material | |
| KR20150085961A (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing Aloe-emodin | |
| KR20240000521A (en) | Hair Serums and Supplements | |
| KR101593628B1 (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing breviscapin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200828 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |